会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • MECHANISM OF ACTION OF PRIMARY CELL DERIVED BIOLOGIC
    • 主要细胞衍生生物学行为机制
    • US20110081313A1
    • 2011-04-07
    • US12995054
    • 2009-05-29
    • John W. Hadden
    • John W. Hadden
    • A61K38/20G01N33/574A61P35/00A61P37/04
    • A61K39/0011A61K31/675A61K36/00A61K45/06A61K2039/545A61K2300/00
    • A method of treating an immune target that is suppressing the immune system and restoring the immune system, including the steps of administering an effective amount of a primary cell derived biologic, modifying populations of B and T cells in blood, activating regional lymph nodes, infiltrating an area adjacent to an immune target with T helper and B cells, infiltrating the immune target with T killer cells and macrophages, and treating the immune target and restoring the immune system. A method of inducing immunization in a patient. A method of destroying a tumor. A method of predicting a favorable treatment outcome to cancer treatment. A method of immune prophylaxis. A method of immune restoration. A method of treating a tumor. A method of preventing tumor escape.
    • 一种治疗免疫系统的免疫系统和恢复免疫系统的方法,包括以下步骤:施用有效量的原代细胞来源的生物,修饰血液中B和T细胞的群体,激活区域性淋巴结,浸润 与T辅助细胞和B细胞的免疫靶标相邻的区域,用T细胞和巨噬细胞浸润免疫靶标,以及治疗免疫靶标并恢复免疫系统。 一种诱导患者免疫的方法。 破坏肿瘤的方法。 预测癌症治疗有利治疗结果的方法。 免疫预防的方法。 免疫恢复的方法。 一种治疗肿瘤的方法。 一种防止肿瘤逃逸的方法。
    • 4. 发明申请
    • VACCINE IMMUNOTHERAPY
    • 疫苗免疫
    • US20100047205A1
    • 2010-02-25
    • US12374732
    • 2007-07-24
    • John W. HaddenKathy SignorelliJames Egan
    • John W. HaddenKathy SignorelliJames Egan
    • A61K38/20A61K38/21A61P35/00
    • A61K39/0011A61K38/191A61K38/2006A61K38/2013A61K38/204A61K38/2053A61K38/217A61K2300/00
    • The present invention provides compositions and methods of immunotherapy to treat cancer or other antigen-producing diseases or lesions. According to one embodiment of the invention, a composition is provided for eliciting an immune response to at (east one antigen in a patient having an antigen-producing disease or lesion, the composition comprising an effective amount of a cytokine mixture, preferably comprising IL-1, IL-2, IL-6, IL-8, IFN-γ (gamma) and TNF-α (alpha). The cytokine mixture acts as an adjuvant with the antigen associated with the antigen-producing disease or lesion to enhance the immune response of the patient to the antigen. Methods are therefore also provided for eliciting an immune response to at least one antigen in a patient having an antigen-producing disease or lesion utilizing the cytokine mixture of the invention. The compositions and methods are useful in the treatment of antigen-producing diseases such as cancer, infectious diseases or persistent lesions.
    • 本发明提供用于治疗癌症或其他产生抗原的疾病或病变的免疫疗法的组合物和方法。 根据本发明的一个实施方案,提供组合物用于在(具有抗原产生性疾病或病变的患者中的东部一种抗原)上引发免疫应答,所述组合物包含有效量的细胞因子混合物,优选包含IL- 1,IL-2,IL-6,IL-8,IFN-γ(γ)和TNF-α(α)。细胞因子混合物作为与产生抗原的疾病或病变相关的抗原的佐剂, 因此,还提供了使用本发明的细胞因子混合物的患有具有产生抗原的疾病或病变的患者中的至少一种抗原的免疫应答的方法,所述组合物和方法可用于 治疗抗原产生疾病如癌症,传染病或持续性病变。
    • 7. 发明申请
    • VACCINE IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS
    • 疫苗免疫用于免疫抑制患者
    • US20100310469A1
    • 2010-12-09
    • US12475957
    • 2010-05-26
    • JOHN W. HADDEN
    • JOHN W. HADDEN
    • A61B5/00A61K38/20A61K38/21A61K39/00C12N5/02A61K38/00A61K31/66A61P29/00A61P35/02
    • A61K38/208A61K38/191A61K38/193A61K38/2006A61K38/2013A61K38/204A61K38/2053A61K38/21A61K2300/00
    • A method of immunotherapy to treat cancer or a synergistic anti-cancer treatment by administering an effective amount of natural cytokine mixture (NCM), an effective amount of cyclophosphamide (CY), or an effective amount of indomethacin (INDO), wherein the NCM, CY, or INDO are administered singly or in communications thereof. An anti-metastatic treatment method by promoting differentiation and maturation of immature dendritic cells in a lymph node; allowing presentation thereof; and preventing development of metastasis. A method of using NCM as a diagnostic skin test for predicting treatment outcome. A method of pre-treating dendritic cells (DC) and a method of treating monocyte defects characterized by sinus histiocytosis or a negative NCM skin test. Compositions and method for eliciting an immune response to endogenous or exogenous tumor antigens.
    • 一种通过施用有效量的天然细胞因子混合物(NCM),有效量的环磷酰胺(CY)或有效量的吲哚美辛(INDO)来治疗癌症或协同抗癌治疗的免疫治疗方法,其中所述NCM, CY或INDO单独施用或通信。 通过促进淋巴结中未成熟树突状细胞的分化和成熟的抗转移治疗方法; 允许呈现; 并预防转移发展。 一种使用NCM作为预测治疗结果的诊断性皮肤试验的方法。 一种预处理树突状细胞(DC)的方法和一种治疗以窦性组织细胞增多或负NCM皮肤试验为特征的单核细胞缺陷的方法。 用于引发对内源性或外源性肿瘤抗原的免疫应答的组合物和方法。
    • 8. 发明授权
    • Immunotherapy for reversing immune suppression
    • 免疫治疗逆转免疫抑制
    • US07731945B2
    • 2010-06-08
    • US10280627
    • 2002-10-26
    • John W. Hadden
    • John W. Hadden
    • A61K45/00A61K47/00
    • A61K39/0011A61K38/19A61K38/2013A61K38/2292A61K39/39A61K2039/5154A61K2039/5158A61K2039/55522A61K2039/55527A61K2039/57A61K2300/00
    • A method for overcoming immune suppression includes the steps of inducing production of naïve T cells and restoring T cell immunity. A method of vaccine immunotherapy includes the steps of inducing production of naïve T cells and exposing the naïve T cells to endogenous or exogenous antigens at an appropriate site. Additionally, a method for unblocking immunization at a regional lymph node includes the steps of promoting differentiation and maturation of immature dendritic cells at a regional lymph node and allowing presentation of processed peptides by resulting mature dendritic cells, thus, for example, exposing tumor peptides to T cells to gain immunization of the T cells. Further, a method of treating cancer and other persistent lesions includes the steps of administering an effective amount of a natural cytokine mixture as an adjuvant to endogenous or exogenous administered antigen to the cancer or other persistent lesions; preferably the natural cytokine mixture is administered in combination with thymosin α1.
    • 克服免疫抑制的方法包括诱导幼稚T细胞的产生和恢复T细胞免疫的步骤。 疫苗免疫治疗的方法包括诱导产生初始T细胞并将初始T细胞暴露于适当位点的内源或外源抗原的步骤。 另外,在局部淋巴结处解除免疫的方法包括以下步骤:促进区域性淋巴结处的未成熟树突状细胞的分化和成熟,并允许通过产生的成熟树突状细胞呈递加工的肽,从而例如将肿瘤肽暴露于 T细胞获得免疫T细胞。 此外,治疗癌症和其它持续性损伤的方法包括以下步骤:将有效量的天然细胞因子混合物作为佐剂施用于内源或外源施用的抗原至癌症或其它持续性损伤; 优选天然细胞因子混合物与胸腺素α1组合施用。
    • 10. 发明授权
    • Vaccine immunotherapy
    • 疫苗免疫治疗
    • US09492517B2
    • 2016-11-15
    • US12374732
    • 2007-07-24
    • John W. HaddenKathy SignorelliJames Egan
    • John W. HaddenKathy SignorelliJames Egan
    • A61K38/20A61K38/21A61K39/00A61K38/19
    • A61K39/0011A61K38/191A61K38/2006A61K38/2013A61K38/204A61K38/2053A61K38/217A61K2300/00
    • The present invention provides compositions and methods of immunotherapy to treat cancer or other antigen-producing diseases or lesions. According to one embodiment of the invention, a composition is provided for eliciting an immune response to at least one antigen in a patient having an antigen-producing disease or lesion, the composition comprising an effective amount of a cytokine mixture, preferably comprising IL-1, IL-2, IL-6, IL-8, IFN-γ (gamma) and TNF-α (alpha). The cytokine mixture acts as an adjuvant with the antigen associated with the antigen-producing disease or lesion to enhance the immune response of the patient to the antigen. Methods are therefore also provided for eliciting an immune response to at least one antigen in a patient having an antigen-producing disease or lesion utilizing the cytokine mixture of the invention. The compositions and methods are useful in the treatment of antigen-producing diseases such as cancer, infectious diseases or persistent lesions.
    • 本发明提供用于治疗癌症或其他产生抗原的疾病或病变的免疫疗法的组合物和方法。 根据本发明的一个实施方案,提供组合物,用于在患有抗原产生疾病或病变的患者中引发对至少一种抗原的免疫应答,所述组合物包含有效量的细胞因子混合物,优选包含IL-1 ,IL-2,IL-6,IL-8,IFN-γ(γ)和TNF-α(α)。 细胞因子混合物作为与产生抗原的疾病或病变相关的抗原的佐剂,以增强患者对抗原的免疫应答。 因此,还提供了使用本发明的细胞因子混合物引起具有产生抗原的疾病或病变的患者中至少一种抗原的免疫应答的方法。 组合物和方法可用于治疗抗原产生性疾病如癌症,感染性疾病或持续性病变。